Hemostemix Inc. (CVE:HEM – Get Free Report) reached a new 52-week low during trading on Tuesday . The company traded as low as C$0.05 and last traded at C$0.06, with a volume of 40000 shares traded. The stock had previously closed at C$0.06.
Hemostemix Stock Performance
The company has a market cap of C$4.94 million, a price-to-earnings ratio of -1.38 and a beta of 0.55. The business has a fifty day moving average price of C$0.07 and a 200 day moving average price of C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Featured Stories
- Five stocks we like better than Hemostemix
- What are earnings reports?
- 3 Steel Stocks Could Soar on New China Tariffs
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Bear Market Funds to Watch This Year
- Most active stocks: Dollar volume vs share volume
- What’s Driving Tesla Lower Ahead of its Earnings?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.